Laura L. Kilarski

ORCID: 0000-0003-0645-3134
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Parkinson's Disease Mechanisms and Treatments
  • Neurological diseases and metabolism
  • Genetic Associations and Epidemiology
  • Lysosomal Storage Disorders Research
  • Treatment of Major Depression
  • Cancer-related molecular mechanisms research
  • Cerebrovascular and genetic disorders
  • Schizophrenia research and treatment
  • Genetic Mapping and Diversity in Plants and Animals
  • Pharmacogenetics and Drug Metabolism
  • Electroconvulsive Therapy Studies
  • Nuclear Receptors and Signaling
  • Tryptophan and brain disorders
  • Genetics and Neurodevelopmental Disorders
  • Attention Deficit Hyperactivity Disorder
  • Moyamoya disease diagnosis and treatment
  • Galectins and Cancer Biology
  • Children's Physical and Motor Development
  • Autophagy in Disease and Therapy
  • Carbohydrate Chemistry and Synthesis
  • RNA modifications and cancer
  • RNA regulation and disease
  • Child and Adolescent Psychosocial and Emotional Development
  • Cancer-related gene regulation
  • Neurological disorders and treatments

University of Bonn
2024

University Hospital Bonn
2024

Klinik und Poliklinik für Psychiatrie und Psychotherapie
2024

Centrum für Integrierte Onkologie
2018-2019

University Hospital Cologne
2017-2019

University of Glasgow
2017

University of Cologne
2016

St George's, University of London
2014-2015

Tel Aviv University
2015

Tel Aviv Sourasky Medical Center
2015

Genome-wide association studies (GWAS) have begun to identify the common genetic component ischaemic stroke (IS). However, IS has considerable phenotypic heterogeneity. Where clinical covariates explain a large fraction of disease risk, covariate informed designs can increase power detect associations. As prevalence rates in are markedly affected by age, and younger onset cases may higher predisposition, we investigated whether an age-at-onset approach could novel associations with its...

10.1371/journal.pgen.1004469 article EN cc-by PLoS Genetics 2014-07-31

(1) Background Pharmacological treatment for psychiatric disorders has shown to only be effective in about one-third of patients, as it is associated with frequent failure, often because side effects, and a long process trial-and-error pharmacotherapy until an tolerable found. This notion emphasizes the urgency personalized medicine approach psychiatry. (2) Methods prospective patient- rater-blinded, randomized, controlled study will investigate effect dose-adjustment antidepressants...

10.3390/ph17020151 article EN cc-by Pharmaceuticals 2024-01-23

Recently, the efficacy of antidepressants, a treatment used by 11% US American adults, has been debated. Thousands randomized controlled trials (RCTs) have to study with majority demonstrating at least moderate superiority over placebo. In contrast, studies found antidepressant effects be unspecific and mainly resulting from The antidepressants may also overestimated due selective publishing selection patients who high chance response in RCTs. Studies shown drugs do not reduce suicidal...

10.1586/14737175.2016.1155985 article EN Expert Review of Neurotherapeutics 2016-02-18

Congenital heart defects (CHD) being the most common congenital malformation, significantly impact mortality and morbidity in children adults. Early detection greatly improves treatment prognosis. Routine pulse oximetry screening fetal echocardiography Germany have advanced early CHD diagnosis. However, a diagnostic gap persists, leaving some cases undetected, worsening This study aimed to evaluate echocardiographic newborns at German university hospital as well record numerous potential...

10.1055/a-2451-6770 article EN Klinische Pädiatrie 2024-12-10

Background: Substance use disorders present a tremendous challenge within contemporary healthcare systems. Specifically, in the domain of opioid (OUDs), several foundational elements are crucial for efficacious management afflicted individuals. Regrettably, premature discontinuation inpatient withdrawal treatment is prevalent phenomenon. This study aims to elucidate prevalence termination among patients with comorbid ADHD. Methods: We conducted comprehensive assessment all participants...

10.3390/jcm13113301 article EN Journal of Clinical Medicine 2024-06-03

Background: Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), caused by mutations in the NOTCH3 gene, is most common monogenic disorder causing lacunar stroke cerebral small vessel disease (SVD). Fabry (FD) due to GLA gene has been suggested as an underdiagnosed cause of stroke, one feature SVD. Previous studies reported varying prevalence CADASIL FD likely subtypes studied; no have looked at a large cohort younger onset We determined...

10.1161/str.46.suppl_1.26 article EN Stroke 2015-02-01

In approximately 3.6% of patients with Parkinson9s disease symptoms start before the age 45 (early onset disease—EOPD). EOPD have a high familial recurrence risk and there are three main autosomal recessive genes. Our aim was to establish prevalence mutations in these genes UK cohort across previous studies. Cases were recruited locally, regionally nationally. We screened 136 cases for pathogenic Parkin, PINK1, DJ-1 exon 41 LRRK2. carried out systematic review studies looking at frequency...

10.1136/jnnp-2011-301993.30 article EN Journal of Neurology Neurosurgery & Psychiatry 2012-02-09
Coming Soon ...